Skip to main content
NVDA+0.31%AAPL+4.12%GOOGL+3.22%MSFT+2.61%AMZN+3.07%TSM+0.07%AVGO+1.46%SPCX+0.02%META+3.10%TSLA-0.44%LLY+0.04%BRK-B-0.67%MU-7.97%JPM+0.97%WMT-1.24%AMD-3.40%ASMLa-0.41%V-0.08%XOM-0.59%JNJ-2.89%0700.HK+3.90%INTC-4.26%MA-0.36%AMAT-2.41%AP2d-3.35%CSCO-4.50%BAC+1.43%ABBV-0.42%CAT-2.08%LRCX-3.20%1398.HK-0.44%COST-0.81%ORCL+3.83%UNH-1.72%GE+1.63%MS+0.58%CVX-0.12%KO-0.97%HSBA.L-0.68%PG+1.01%0005.HK+1.77%HD+1.04%GS+0.98%NFLX+0.10%0857.HK-0.31%ARM-1.32%1816.HK+0.77%NVS+0.32%GEV-1.45%BABA+4.81%NZDJPY+1.78%NZDUSD+1.47%GBPJPY+1.31%CADJPY+1.16%AUDJPY+1.09%NZDCHF+1.03%EURNZD-1.02%GBPUSD+0.99%USDTHB+0.94%GBPSGD+0.90%USDCAD-0.82%USDSEK-0.79%EURJPY+0.77%CHFJPY+0.76%AUDUSD+0.73%GBPZAR+0.73%AUDNZD-0.69%NZDCAD+0.63%GBPCHF+0.59%EURGBP-0.56%NZDSGD+0.51%USDPLN-0.49%GBPNZD-0.47%PLNJPY+0.46%NZDMXN+0.44%EURUSD+0.43%USDCHF-0.42%EURSEK-0.42%CADCHF+0.42%GBPTRY+0.41%USDNOK-0.41%EURHKD+0.39%EURCAD-0.39%NOKJPY+0.39%USDDKK-0.38%CHFSGD+0.37%EURAUD-0.34%USDJPY+0.33%USDZAR-0.33%AUDCHF+0.32%GBPHKD+0.32%AUDSGD+0.31%EURCNH+0.29%GBPMXN-0.28%CHFSEK-0.28%GBPAUD+0.26%USDMXN-0.23%EURSGD+0.22%USDCNH-0.21%GBPCAD+0.17%USDILS+0.16%USDSGD-0.15%SGDJPY+0.14%EURCZK-0.12%CHFNOK+0.11%USDTRY+0.11%EURPLN-0.10%AUDDKK+0.08%AUDCAD-0.06%AUDNOK+0.05%EURZAR+0.05%USDCOP-0.04%EURNOK-0.02%EURCHF+0.01%USDHKD0.00%EURDKK0.00%XPTUSD+2.91%GAGUSD-1.66%XAGUSD-1.64%USOIL+0.78%XNGUSD+0.54%UKOIL+0.41%HG1+0.34%XAUUSD+0.04%GAUUSD+0.04%COFFEE0.00%COTTON0.00%W10.00%BTCUSDT-14.41%BTCUSD+0.30%ETHUSD+2.73%USDTUSD+0.02%BNBUSDT-7.85%XRPUSD+0.36%SOLUSD-0.83%TRXUSDT-0.76%DOGEUSD-0.77%ZECUSDT+2.23%ADAUSDT-34.21%XMRUSDT+0.69%XLMUSD+1.63%LINKUSD+1.78%XLMUSDT+7.16%BCHUSDT-3.33%AVAXUSDT-28.45%TONUSD+6.48%SUIUSDT-20.98%LTCUSD-0.10%TONUSDT+27.64%HBARUSDT-0.57%SUIUSD-0.63%UNIUSD-0.99%TAOUSDT-0.28%UNIUSDT+10.98%NEARUSDT+49.16%AAVEUSD-1.17%DOTUSDT-1.81%ETCUSDT-15.87%ICPUSDT-0.52%PEPEUSD+10096381.47%WLDUSDT-0.99%ONDOUSDT+4.19%ATOMUSDT-0.22%JUPUSDT-1.28%INJUSDT+3.03%ARBUSDT-1.69%PENGUUSDT+99162.08%FETUSDT-0.28%TIAUSDT+1.58%SEIUSDT+0.12%STXUSDT-0.37%PYTHUSDT-1.57%IMXUSDT-1.22%OPUSDT+0.49%GRTUSDT-0.84%AXSUSDT-0.65%NVDA+0.31%AAPL+4.12%GOOGL+3.22%MSFT+2.61%AMZN+3.07%TSM+0.07%AVGO+1.46%SPCX+0.02%META+3.10%TSLA-0.44%LLY+0.04%BRK-B-0.67%MU-7.97%JPM+0.97%WMT-1.24%AMD-3.40%ASMLa-0.41%V-0.08%XOM-0.59%JNJ-2.89%0700.HK+3.90%INTC-4.26%MA-0.36%AMAT-2.41%AP2d-3.35%CSCO-4.50%BAC+1.43%ABBV-0.42%CAT-2.08%LRCX-3.20%1398.HK-0.44%COST-0.81%ORCL+3.83%UNH-1.72%GE+1.63%MS+0.58%CVX-0.12%KO-0.97%HSBA.L-0.68%PG+1.01%0005.HK+1.77%HD+1.04%GS+0.98%NFLX+0.10%0857.HK-0.31%ARM-1.32%1816.HK+0.77%NVS+0.32%GEV-1.45%BABA+4.81%NZDJPY+1.78%NZDUSD+1.47%GBPJPY+1.31%CADJPY+1.16%AUDJPY+1.09%NZDCHF+1.03%EURNZD-1.02%GBPUSD+0.99%USDTHB+0.94%GBPSGD+0.90%USDCAD-0.82%USDSEK-0.79%EURJPY+0.77%CHFJPY+0.76%AUDUSD+0.73%GBPZAR+0.73%AUDNZD-0.69%NZDCAD+0.63%GBPCHF+0.59%EURGBP-0.56%NZDSGD+0.51%USDPLN-0.49%GBPNZD-0.47%PLNJPY+0.46%NZDMXN+0.44%EURUSD+0.43%USDCHF-0.42%EURSEK-0.42%CADCHF+0.42%GBPTRY+0.41%USDNOK-0.41%EURHKD+0.39%EURCAD-0.39%NOKJPY+0.39%USDDKK-0.38%CHFSGD+0.37%EURAUD-0.34%USDJPY+0.33%USDZAR-0.33%AUDCHF+0.32%GBPHKD+0.32%AUDSGD+0.31%EURCNH+0.29%GBPMXN-0.28%CHFSEK-0.28%GBPAUD+0.26%USDMXN-0.23%EURSGD+0.22%USDCNH-0.21%GBPCAD+0.17%USDILS+0.16%USDSGD-0.15%SGDJPY+0.14%EURCZK-0.12%CHFNOK+0.11%USDTRY+0.11%EURPLN-0.10%AUDDKK+0.08%AUDCAD-0.06%AUDNOK+0.05%EURZAR+0.05%USDCOP-0.04%EURNOK-0.02%EURCHF+0.01%USDHKD0.00%EURDKK0.00%XPTUSD+2.91%GAGUSD-1.66%XAGUSD-1.64%USOIL+0.78%XNGUSD+0.54%UKOIL+0.41%HG1+0.34%XAUUSD+0.04%GAUUSD+0.04%COFFEE0.00%COTTON0.00%W10.00%BTCUSDT-14.41%BTCUSD+0.30%ETHUSD+2.73%USDTUSD+0.02%BNBUSDT-7.85%XRPUSD+0.36%SOLUSD-0.83%TRXUSDT-0.76%DOGEUSD-0.77%ZECUSDT+2.23%ADAUSDT-34.21%XMRUSDT+0.69%XLMUSD+1.63%LINKUSD+1.78%XLMUSDT+7.16%BCHUSDT-3.33%AVAXUSDT-28.45%TONUSD+6.48%SUIUSDT-20.98%LTCUSD-0.10%TONUSDT+27.64%HBARUSDT-0.57%SUIUSD-0.63%UNIUSD-0.99%TAOUSDT-0.28%UNIUSDT+10.98%NEARUSDT+49.16%AAVEUSD-1.17%DOTUSDT-1.81%ETCUSDT-15.87%ICPUSDT-0.52%PEPEUSD+10096381.47%WLDUSDT-0.99%ONDOUSDT+4.19%ATOMUSDT-0.22%JUPUSDT-1.28%INJUSDT+3.03%ARBUSDT-1.69%PENGUUSDT+99162.08%FETUSDT-0.28%TIAUSDT+1.58%SEIUSDT+0.12%STXUSDT-0.37%PYTHUSDT-1.57%IMXUSDT-1.22%OPUSDT+0.49%GRTUSDT-0.84%AXSUSDT-0.65%

J&J lifts 2026 outlook after Q2 earnings

NEWS

July 15, 2026 at 15:31 UTC

2 min read
Unbranded prescription bottles on a shelf illustrating strong pharma results in JNJ Q2 earnings outlook

Key Points

  • 01J&J posted Q2 2026 sales of $25.31 billion and EPS of $2.90
  • 02Innovative Medicine drove $16.38 billion in quarterly revenue
  • 03MedTech revenue of $8.93 billion slightly missed expectations
  • 04Full-year 2026 EPS and sales guidance were both raised

Strong Q2 results led by Innovative Medicine

Johnson & Johnson (JNJ) reported second-quarter 2026 sales of $25.31 billion and adjusted earnings per share of $2.90. Performance was driven by its pharmaceutical-focused Innovative Medicine segment, which generated $16.38 billion in revenue. Oncology products, including key cancer therapies, were highlighted as primary contributors to this growth. The company also noted a marked increase in sales of Tremfya, which rose to about $2.0 billion in the quarter.

The strength in Innovative Medicine helped offset softer areas elsewhere in the business. Management pointed to the oncology portfolio and immunology products as important growth engines supporting the overall earnings outcome. These results formed the basis for the company’s decision to raise its full-year 2026 financial guidance.

MedTech softness and Abiomed pressure

The MedTech segment recorded second-quarter 2026 revenue of $8.93 billion. This figure was slightly below analyst expectations of about $8.97 billion, representing a modest shortfall relative to consensus. Within MedTech, the Abiomed unit reported sales of roughly $440 million, down about 2% year over year.

The decline at Abiomed followed publication of a U.K. study that raised questions about the use of Impella heart pumps in certain high-risk coronary procedures. The company’s chief financial officer said the study weighed on the franchise’s performance during the quarter. Management indicated it plans to address these concerns by releasing additional clinical data, including a large data set expected in the first half of next year.

Raised full-year 2026 guidance

On the back of its second-quarter results, Johnson & Johnson (JNJ) increased its full-year 2026 outlook. The company now expects adjusted earnings per share between $11.60 and $11.75. Reported sales guidance was raised to a range of $100.8 billion to $101.4 billion, implying a midpoint of about $101.1 billion in revenue for the year.

Management’s updated guidance reflects confidence in continued momentum from the Innovative Medicine portfolio, despite recent headwinds in the MedTech segment. While MedTech results slightly trailed expectations and Abiomed sales declined, the overall performance and outlook suggest the company anticipates stronger contributions from its core medicines business for the remainder of 2026.

Key Takeaways

  • 01Innovative Medicine’s oncology and immunology products are central to Johnson & Johnson (JNJ)’s current growth and underpin its raised 2026 outlook.
  • 02MedTech performance is more mixed, with a small revenue miss and pressure on Abiomed following clinical questions around Impella pumps.
  • 03Despite segment-level challenges, higher full-year EPS and sales guidance indicate management expects overall business strength to continue into 2026.

References

  1. https://www.benzinga.com/markets/earnings/26/07/60468576/johnson-johnson-finds-growth-beyond-legacy-drugs-lifts-2026-outlook
  2. https://www.chartmill.com/news/JNJ/Chartmill-50997-Johnson-Johnson-NYSEJNJ-Raises-Full-Year-Guidance-After-In-Line-Q2-Results
  3. https://www.jnj.com/media-center/press-releases/johnson-johnson-reports-q2-2026-results-raises-2026-outlook
  4. https://www.stocktitan.net/news/JNJ/johnson-johnson-reports-q2-2026-results-raises-2026-b50atm4ecwl7.html